Physician profile
Donald E Shows
NPI 1700895497
$2,661.11
in general payments reported to CMS, 2019-2025
23 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $357 · 2021: $616 · 2022: $426 · 2023: $380 · 2024: $302 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $620.67 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.28 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $260.03 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.93 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $177.02 | 2019-2025 | Camzyos |
| Abbott Laboratories | $175.19 | 2021 | |
| Amgen INC. | $123.97 | 2019-2023 | Repatha |
| Astellas Pharma US INC | $113.79 | 2019-2020 | |
| Cardiva Medical, INC. | $111.43 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Merck Sharp & Dohme LLC | $90.66 | 2022-2023 | Verquvo |
| Amarin Pharma, INC. | $87.46 | 2019-2021 | |
| Medtronic, INC. | $75.12 | 2022-2025 | Cobalt Dr Mri Surescan, Micra |
| Pfizer INC. | $67.73 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $52.20 | 2019-2021 | |
| Philips North America LLC | $44.68 | 2023-2024 | (Ck7) Extended Holter, (Ck4) Mcot |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $40.59 | 2022-2024 | Angiojet Ultra 5000a |
| Edwards Lifesciences Corporation | $36.43 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kestra Medical Technology Services, INC. | $26.46 | 2025 | Assure Wcd |
| Abiomed | $20.56 | 2023 | Impella |
| Novo Nordisk INC | $20.22 | 2024 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $14.00 | 2019 | |
| Gilead Sciences, INC. | $11.84 | 2019 | |
| Medtronic Vascular, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Shows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.